Analysts Conflicted on These Healthcare Names: Dexcom (DXCM), Vertex Pharmaceuticals (VRTX) and Royalty Pharma (RPRX)
Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Dexcom (DXCM – Research Report), Vertex Pharmaceuticals (VRTX – Research Report) and Royalty Pharma (RPRX – Research Report).
Valentine's Day Sale - 70% Off
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Dexcom (DXCM)
In a report released today, Travis Steed from Bank of America Securities reiterated a Buy rating on Dexcom, with a price target of $100.00. The company’s shares closed last Thursday at $65.08, close to its 52-week low of $62.34.
According to TipRanks.com, Steed is a 4-star analyst with an average return of
Currently, the analyst consensus on Dexcom is a Strong Buy with an average price target of $84.19, a 23.8% upside from current levels. In a report issued on January 30, TipRanks – PerPlexity also upgraded the stock to Buy with a $85.00 price target.
See the top stocks recommended by analysts >>
Vertex Pharmaceuticals (VRTX)
Scotiabank analyst Louise Chen maintained a Buy rating on Vertex Pharmaceuticals today and set a price target of $558.00. The company’s shares closed last Thursday at $465.02.
According to TipRanks.com, Chen is a 3-star analyst with an average return of
Currently, the analyst consensus on Vertex Pharmaceuticals is a Strong Buy with an average price target of $549.45, which is a 18.9% upside from current levels. In a report released today, Oppenheimer also upgraded the stock to Buy with a $540.00 price target.
Royalty Pharma (RPRX)
Evercore ISI analyst Umer Raffat maintained a Hold rating on Royalty Pharma yesterday. The company’s shares closed last Thursday at $44.80.
According to TipRanks.com, Raffat is a 4-star analyst with an average return of
Royalty Pharma has an analyst consensus of Strong Buy, with a price target consensus of $51.43, implying a 16.3% upside from current levels. In a report released yesterday, TipRanks – Anthropic also downgraded the stock to Hold with a $47.00 price target.
